- Home
- ROIV vs CACI Comparison
ROIV vs CACI Comparison
Compare ROIV & CACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- CACI
- Stock Information
- Founded
- ROIV 2014
- CACI 1962
- Country
- ROIV United Kingdom
- CACI United States
- Employees
- ROIV N/A
- CACI N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- CACI EDP Services
- Sector
- ROIV Health Care
- CACI Technology
- Exchange
- ROIV Nasdaq
- CACI Nasdaq
- Market Cap
- ROIV 8.4B
- CACI 7.3B
- IPO Year
- ROIV N/A
- CACI 1979
- Fundamental
- Price
- ROIV $10.79
- CACI $479.45
- Analyst Decision
- ROIV Buy
- CACI Buy
- Analyst Count
- ROIV 4
- CACI 13
- Target Price
- ROIV $17.50
- CACI $502.83
- AVG Volume (30 Days)
- ROIV 5.9M
- CACI 369.5K
- Earning Date
- ROIV 05-29-2025
- CACI 04-23-2025
- Dividend Yield
- ROIV N/A
- CACI N/A
- EPS Growth
- ROIV N/A
- CACI 22.32
- EPS
- ROIV N/A
- CACI 21.19
- Revenue
- ROIV $122,585,000.00
- CACI $8,361,975,000.00
- Revenue This Year
- ROIV N/A
- CACI $14.65
- Revenue Next Year
- ROIV N/A
- CACI $7.25
- P/E Ratio
- ROIV N/A
- CACI $22.56
- Revenue Growth
- ROIV 140.04
- CACI 14.16
- 52 Week Low
- ROIV $8.73
- CACI $318.60
- 52 Week High
- ROIV $13.06
- CACI $588.26
- Technical
- Relative Strength Index (RSI)
- ROIV 50.06
- CACI 71.28
- Support Level
- ROIV $10.58
- CACI $460.14
- Resistance Level
- ROIV $11.77
- CACI $483.10
- Average True Range (ATR)
- ROIV 0.34
- CACI 10.82
- MACD
- ROIV -0.07
- CACI -1.12
- Stochastic Oscillator
- ROIV 17.65
- CACI 91.09
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CACI CACI International Inc.
CACI International Inc is an information solutions and services provider, offering information solutions and services to its customers. The company's primary customers are agencies and departments of the U.S. government, which account for the vast majority of the firm's revenue. It provides information solutions and services supporting national security missions and government modernization for intelligence, defense, and federal civilian customers. Some of the services provided by the company are functional software development, data, and business analysis, IT operations support, naval architecture, and life cycle support intelligence among others. The company's operating segments are; Domestic operations and International operations. It derives key revenue from the Domestic segment.